TALVEY® (talquetamab-tgvs) HCP

Evolve Your Strategy with TALVEY^®

TALVEY^® is a first-in-class GPRC5D × CD3 targeting agent^1,2

Explore efficacy data

See safety profile

For the treatment of adult patients with RRMM who have received ≥4 prior lines of therapy, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Powerful efficacy demonstrated with TALVEY^® monotherapy^1,3

Naïve to T-cell redirection therapy*

73.6% ORR^† with Q2W dosing (95% CI, 63.0%-82.4%) (n=65/87)
73% ORR^† with QW dosing (95% CI, 63.2%-81.4%) (n=73/100)

Exposed to T-cell redirection therapy*

72% ORR^† with QW dosing (95% CI, 53%-86%) (n=23/32)^‡

Versatile treatment option for patients naïve and exposed to T-cell redirection therapy¹

The MonumenTAL-1 trial included patients who were naïve and exposed to T-cell redirection therapy.^*‡

Flexible dosing: either Q2W or QW dosing schedule right from the start¹

Q2W and QW dosing begins after the respective step-up dosing schedule.

MonumenTAL-1 study design: The efficacy of TALVEY^® was evaluated in 219 patients with relapsed or refractory multiple myeloma in the single-arm, open-label, multicenter, phase 1/2 trial. The trial included patients who had received ≥3 prior systemic therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Efficacy was based on ORR and DOR as assessed by an IRC using IMWG criteria.^1,3,4§

^*T-cell redirection therapy refers to both CAR-T and bispecific antibody therapy.

^†ORR: sCR+CR+VGPR+PR.

^‡Of 32 patients, 81% had prior CAR-T and 25% had prior bispecific antibody therapy.

^§Efficacy results reflect patients who received ≥4 prior lines of therapy.

CAR-T, chimeric antigen receptor-T cell; CD, cluster of differentiation; CI, confidence interval; CR, complete response; DOR, duration of response; GPRC5D, G protein-coupled receptor class C group 5 member D; IMWG, International Myeloma Working Group; IRC, Independent Review Committee; MM, multiple myeloma; ORR, overall response rate; PI, proteasome inhibitor; PR, partial response; QW, once weekly; Q2W, every 2 weeks; REMS, Risk Evaluation and Mitigation Strategy; RRMM, relapsed or refractory multiple myeloma; sCR, stringent complete response; VGPR, very good partial response.

TALVEY^® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
U.S. FDA approves TALVEY^® (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. News release. Janssen Biotech, Inc.; August 10, 2023. Accessed January 31, 2024. https://www.janssen.com/fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily
Data on File. Janssen Biotech, Inc.
A study of talquetamab in participants with relapsed or refractory multiple myeloma. ClinicalTrials.gov identifier: NCT04634552. Updated April 24, 2024. Accessed April 26, 2024. https://clinicaltrials.gov/study/NCT04634552

Need Help?

Chat With Medical Information

Evolve Your Strategy with TALVEY®

Powerful efficacy demonstrated with TALVEY® monotherapy1,3

Versatile treatment option for patients naïve and exposed to T-cell redirection therapy1

Flexible dosing: either Q2W or QW dosing schedule right from the start1

References

Need Help?

Evolve Your Strategy with TALVEY^®

Powerful efficacy demonstrated with TALVEY^® monotherapy^1,3

Versatile treatment option for patients naïve and exposed to T-cell redirection therapy¹

Flexible dosing: either Q2W or QW dosing schedule right from the start¹